A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures. Pregabalin will be administered in equally divided daily doses for 1 year, in either capsule or liquid oral formulation.
Inclusion Criteria:
Exclusion Criteria:
Pittsburgh, Pennsylvania 15224, United States
Sarajevo, Canton Sarajevo, Bosnia and Herzegovina 71000, Bosnia and Herzegovina
Prijedor, Republika Srpska 79101, Bosnia and Herzegovina
Brno - Cerna Pole, 613 00, Czechia
Dhantoli, Nagpur, Maharashtra 440012, India
Ancona, 60123, Italy
Diliman, Quezon City, 1105, Philippines
Wroclaw, 54-049, Poland
Pgt. Roshchino, Leningradskaya Oblast' 188820, Russia
Bangkoknoi, Bangkok 10700, Thailand
Izmir, Bornova/izmir 35100, Turkey (Türkiye)
Trabzon, Farabi 61080, Turkey (Türkiye)
Izmir, Konak 35210, Turkey (Türkiye)
Dnipropetrovsk, 49100, Ukraine
Kharkiv, 61068, Ukraine
Kyiv, 04209, Ukraine
Lviv, 79010, Ukraine
Odesa, 65006, Ukraine
S. Oleksandrivka, Kominternivskyi R-n, Odeska Obl., 67513, Ukraine
Uzhhorod, 88018, Ukraine
Zaporizhzhya, 69068, Ukraine